

**VCUHS ANTIFUNGAL SUSCEPTIBILITY TABLES**  
**JANUARY – DECEMBER 2024**  
**Department of Pathology - Microbiology/Immunology**

**Table 1. Activity of selected antifungals against yeast**

Percentage (%) of Organisms Susceptible				
Organism	Number Tested	Micafungin	Fluconazole <sup>b</sup>	Voriconazole
<i>Candida albicans</i>	84	100	94	94
<i>Candida glabrata</i>	54	100	74	- <sup>a</sup>
<i>Candida parapsilosis</i>	39	94	92	92
<i>Candida auris</i> <sup>d</sup>	45 <sup>c</sup>	52	0	

<sup>a</sup> Current data are insufficient to demonstrate a correlation between *in vitro* susceptibility testing and clinical outcomes per CLSI M100 guidelines.

<sup>b</sup> Fluconazole results include Susceptible Dose Dependent (SDD) isolates.

<sup>c</sup> Data included from January 2023 until December 2024 due to data with fewer than 30 isolates being considered statistically unreliable.

<sup>d</sup> There are currently no established *C. auris*-specific susceptibility breakpoints. The interpretations given should be considered as a general guide and not as definitive breakpoints for resistance. These CDC tentative breakpoints are defined based on those established for closely related *Candida* species and on expert opinion.

**Data collected by the Clinical Microbiology Laboratory, Department of Pathology**  
**CLSI M100-ed34 and M27M44-ed3 Interpretation breakpoints were applied unless otherwise stated.**